文献速递湿疹皮炎与荨麻疹

特应性皮炎系统治疗随机对照试验中的安慰剂反应:系统综述与荟萃分析

Placebo responses in randomized controlled trials for systemic therapy in atopic dermatitis: A systematic review and meta-analysis.
PubMed 文献 · J Am Acad Dermatol · 2019-06-13

该系统综述与荟萃分析纳入2007-2018年发表的64项特应性皮炎系统治疗随机对照试验,评估安慰剂反应的预测因素。多变量混合模型显示,允许合并使用处方外用治疗、研究时长≥3个月及治疗组数较少与EASI、瘙痒NRS/VAS和DLQI的安慰剂反应增加相关。结论提示通过双盲/三盲设计、平衡性别分布、禁止合并处方外用治疗及缩短研究时长可降低安慰剂反应。

要点

  • 合并使用处方外用治疗、研究时长≥3个月及治疗组数较少与安慰剂反应增加相关。
  • EASI的安慰剂反应在男性比例较高、基线轻度至中度EASI及无盲法设计的研究中增加。
  • 瘙痒NRS/VAS的安慰剂反应与男性比例较高及基线中度至重度瘙痒评分相关。

核心结论

  • 通过双盲和三盲设计、平衡患者性别分布、禁止合并使用处方外用治疗及缩短研究时长,可降低特应性皮炎系统治疗临床试验中的安慰剂反应。

研究设计与样本

  • 系统综述与荟萃分析,纳入2007-2018年发表的64项特应性皮炎系统治疗随机对照试验,检索Cochrane Library、Medline、Embase、GREAT、LILACS和Scopus。

主要发现

  • 合并使用处方外用治疗、研究时长≥3个月及治疗组数较少与EASI、瘙痒NRS/VAS和DLQI的安慰剂反应增加相关。
  • EASI的安慰剂反应在男性患者比例较高、基线平均EASI为轻度至中度及无盲法设计的研究中增加。
  • 瘙痒NRS和VAS的安慰剂反应与男性患者比例较高及基线平均瘙痒评分为中度至重度相关。

关键数值与推荐

  • 安慰剂反应以EASI、SCORAD、瘙痒NRS、瘙痒VAS和DLQI的Cohen D评估。
  • 使用多变量混合模型分析安慰剂反应的预测因素。

临床怎么用

  • 设计特应性皮炎系统治疗试验时,应采用双盲或三盲设计、平衡性别分布、禁止合并处方外用治疗并缩短研究时长,以减少安慰剂反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis (AD) has a variable disease course and intermittent triggers, and responses to topical therapy vary, potentially affecting the magnitude of the placebo response in AD trials. OBJECTIVE: To determine the predictors of increased placebo response in randomized controlled trials of AD. METHODS: We performed a systematic review and meta-analysis of randomized controlled trials for systemic therapy in AD published during 2007-2018. We searched the Cochrane Library, Medline, Embase, Global Resource for EczemA Trials (GREAT), Literature of the Latin American and Caribbean Health Sciences (LILACS), and Scopus. Two authors performed study selection and data extraction. Multivariable mixed models were constructed for Cohen D of Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), numeric rating scale (NRS)-itch and visual analog scale (VAS)-itch, and Dermatology Life Quality Index (DLQI). RESULTS: Overall, 64 trials were included. Use of concomitant topical therapy prescriptions, study duration ≥3 months, and fewer treatment arms were associated with an increased placebo response for EASI, NRS- and VAS-itch, and DLQI. For EASI, the placebo response was increased in studies with a higher proportion of male patients, mild-moderate mean baseline EASI scores, and no blinding. For NRS-itch, and VRS-itch, higher placebo responses were associated with higher proportions of male patients and moderate-severe mean itch scores at baseline. CONCLUSION: Placebo responses can be reduced in clinical trials of systemic therapy in AD by incorporating double- and triple-blinding, balancing the sex distribution of patients, disallowing concomitant use of prescription topical therapy, and having shorter study durations.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Lee HH, Patel KR, Rastogi S, et al. Placebo responses in randomized controlled trials for systemic therapy in atopic dermatitis: A systematic review and meta-analysis. J Am Acad Dermatol. 2019. PMID: 31202874. doi:10.1016/j.jaad.2019.05.102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。